

Cinzia Costa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4723509/publications.pdf>

Version: 2024-02-01

108
papers

5,055
citations

87843

38
h-index

98753

67
g-index

110
all docs

110
docs citations

110
times ranked

6987
citing authors

#	ARTICLE	IF	CITATIONS
1	Cognitive Decline Risk Stratification in People with Late-Onset Epilepsy of Unknown Etiology: An Electroencephalographic Connectivity and Graph Theory Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 893-901.	1.2	6
2	Clinical and Instrumental Characterization of Patients With Late-Onset Epilepsy. <i>Frontiers in Neurology</i> , 2022, 13, 851897.	1.1	4
3	Epilepsy and Alzheimer's Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies. <i>Current Neuropharmacology</i> , 2022, 20, 2029-2033.	1.4	4
4	Developmental impaired Akt signaling in the Shank1 and Shank3 double knock-out mice. <i>Molecular Psychiatry</i> , 2021, 26, 1928-1944.	4.1	26
5	Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy. <i>Mechanisms of Ageing and Development</i> , 2021, 194, 111434.	2.2	11
6	Temporal lobe dysfunction in late-onset epilepsy of unknown origin. <i>Epilepsy and Behavior</i> , 2021, 117, 107839.	0.9	6
7	Italian cohort of Lafora disease: Clinical features, disease evolution, and genotype-phenotype correlations. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117409.	0.3	11
8	Amyloid- β : a potential link between epilepsy and cognitive decline. <i>Nature Reviews Neurology</i> , 2021, 17, 469-485.	4.9	60
9	An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5991.	1.8	28
10	CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors. <i>Neurobiology of Disease</i> , 2021, 158, 105473.	2.1	8
11	Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases. <i>Frontiers in Neurology</i> , 2021, 12, 800524.	1.1	3
12	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. <i>Cell Reports</i> , 2021, 37, 110094.	2.9	38
13	Rivaroxaban Plasma Levels and Levetiracetam. <i>Annals of Internal Medicine</i> , 2020, 173, 772.	2.0	2
14	Rivaroxaban Plasma Levels and Levetiracetam: A Case Report. <i>Annals of Internal Medicine</i> , 2020, 173, 71-72.	2.0	20
15	Effect of Brivaracetam on Efficacy and Tolerability in Patients With Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study. <i>Frontiers in Neurology</i> , 2020, 11, 813.	1.1	19
16	Late-onset epilepsy with unknown etiology: A pilot study on neuropsychological profile, cerebrospinal fluid biomarkers, and quantitative EEG characteristics. <i>Alzheimer's and Dementia</i> , 2020, 16, e045129.	0.4	0
17	Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics. <i>Frontiers in Neurology</i> , 2020, 11, 199.	1.1	24
18	Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. <i>Neurobiology of Disease</i> , 2020, 140, 104848.	2.1	19

#	ARTICLE	IF	CITATIONS
19	Management of epilepsy in brain tumors. <i>Neurological Sciences</i> , 2019, 40, 2217-2234.	0.9	33
20	Hippocampal epileptogenesis in autoimmune encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2261-2269.	1.7	20
21	An Italian multicentre study of perampanel in progressive myoclonus epilepsies. <i>Epilepsy Research</i> , 2019, 156, 106191.	0.8	19
22	Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. <i>Journal of Neurology</i> , 2019, 266, 2273-2276.	1.8	4
23	Epilepsy, headache, and chronic pain. , 2019, , 187-205.		0
24	HCN ion channels and accessory proteins in epilepsy: genetic analysis of a large cohort of patients and review of the literature. <i>Epilepsy Research</i> , 2019, 153, 49-58.	0.8	32
25	Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions. <i>Cephalalgia</i> , 2019, 39, 1333-1338.	1.8	8
26	Striatal spreading depolarization: Possible implication in levodopa-induced dyskinesia-like behavior. <i>Movement Disorders</i> , 2019, 34, 832-844.	2.2	6
27	Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study. <i>Epilepsy and Behavior</i> , 2019, 101, 106592.	0.9	21
28	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. <i>Neurobiology of Aging</i> , 2019, 73, 61-67.	1.5	75
29	Two-Year Longitudinal Monitoring of Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 15-35.	1.2	34
30	Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. <i>Current Neuropharmacology</i> , 2019, 17, 926-946.	1.4	190
31	Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. <i>Neurobiology of Disease</i> , 2018, 113, 97-108.	2.1	27
32	Lacosamide protects striatal and hippocampal neurons from <i>in vitro</i> ischemia without altering physiological synaptic plasticity. <i>Neuropharmacology</i> , 2018, 135, 424-430.	2.0	13
33	Liverpool Adverse Events Profile: Italian validation and predictive value for dropout from antiepileptic treatment in people with epilepsy. <i>Epilepsy and Behavior</i> , 2018, 81, 111-114.	0.9	10
34	Epilepsy in hemiplegic migraine: Genetic mutations and clinical implications. <i>Cephalalgia</i> , 2018, 38, 361-373.	1.8	36
35	Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?. <i>Cephalalgia</i> , 2018, 38, 274-282.	1.8	19
36	A novel <i>de novo</i> HCN1 loss-of-function mutation in genetic generalized epilepsy causing increased neuronal excitability. <i>Neurobiology of Disease</i> , 2018, 118, 55-63.	2.1	47

#	ARTICLE	IF	CITATIONS
37	Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature. <i>International Journal of Molecular Sciences</i> , 2018, 19, 345.	1.8	7
38	A Loss-of-Function HCN4 Mutation Associated With Familial Benign Myoclonic Epilepsy in Infancy Causes Increased Neuronal Excitability. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 269.	1.4	25
39	Late onset epilepsy and Alzheimer's disease: exploring the dual pathogenic role of amyloid- β . <i>Brain</i> , 2018, 141, e60-e60.	3.7	12
40	Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 118, 1-8.	2.1	22
41	Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. <i>European Journal of Neurology</i> , 2017, 24, 1283-1289.	1.7	30
42	Clinical features and outcome of 6 new patients carrying de novo <i>KCNB1</i> gene mutations. <i>Neurology: Genetics</i> , 2017, 3, e206.	0.9	53
43	Epilepsy Comorbidity. <i>Headache</i> , 2017, , 41-63.	0.2	0
44	Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center. <i>PLoS ONE</i> , 2017, 12, e0180470.	1.1	23
45	Epilepsy, amyloid- β , and D1 dopamine receptors: a possible pathogenetic link?. <i>Neurobiology of Aging</i> , 2016, 48, 161-171.	1.5	71
46	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. <i>Scientific Reports</i> , 2016, 6, 20926.	1.6	68
47	Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. <i>Journal of Neuro-Oncology</i> , 2016, 129, 355-361.	1.4	25
48	Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit. <i>Biological Psychiatry</i> , 2016, 79, 402-414.	0.7	77
49	Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs. <i>Neurochemical Research</i> , 2016, 41, 340-352.	1.6	14
50	Migraine and epilepsy: what value today?. <i>Journal of Headache and Pain</i> , 2015, 16, A44.	2.5	2
51	O064. Antiepileptic drugs in migraine and epilepsy disorders: who is at increased risk of adverse events?. <i>Journal of Headache and Pain</i> , 2015, 16, A69.	2.5	0
52	Endogenous 17 β -estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 192.	1.8	43
53	Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 123-133.	1.5	30
54	A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy. <i>Cephalalgia</i> , 2014, 34, 68-72.	1.8	28

#	ARTICLE	IF	CITATIONS
55	Brain arteriovenous malformations and seizures: an Italian study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 284-288.	0.9	44
56	Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice. <i>Experimental Neurology</i> , 2014, 261, 320-327.	2.0	25
57	Cortical spreading depression as a target for anti-migraine agents. <i>Journal of Headache and Pain</i> , 2013, 14, 62.	2.5	110
58	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. <i>Neurobiology of Disease</i> , 2013, 52, 229-236.	2.1	155
59	Ischemic-LTP in Striatal Spiny Neurons of both Direct and Indirect Pathway Requires the Activation of D1-Like Receptors and NO/Soluble Guanylate Cyclase/cGMP Transmission. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 278-286.	2.4	13
60	Protective Effects of Zonisamide Against Rotenone-Induced Neurotoxicity. <i>Neurochemical Research</i> , 2013, 38, 2631-2639.	1.6	17
61	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18985-18990.	3.3	113
62	Mechanisms underlying altered striatal synaptic plasticity in old A53T- α synuclein overexpressing mice. <i>Neurobiology of Aging</i> , 2012, 33, 1792-1799.	1.5	37
63	A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. <i>PLoS ONE</i> , 2012, 7, e38312.	1.1	18
64	Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. <i>Brain</i> , 2012, 135, 1884-1899.	3.7	124
65	Striatum-hippocampus balance: From physiological behavior to interneuronal pathology. <i>Progress in Neurobiology</i> , 2011, 94, 102-114.	2.8	43
66	Neural 17 β -estradiol facilitates long-term potentiation in the hippocampal CA1 region. <i>Neuroscience</i> , 2011, 192, 67-73.	1.1	50
67	A critical role of NO/cGMP/PKG dependent pathway in hippocampal post-ischemic LTP: Modulation by zonisamide. <i>Neurobiology of Disease</i> , 2011, 44, 185-191.	2.1	23
68	c-Jun N-terminal Kinase Regulates Soluble A β 2 Oligomers and Cognitive Impairment in AD Mouse Model. <i>Journal of Biological Chemistry</i> , 2011, 286, 43871-43880.	1.6	74
69	Occipital arteriovenous malformations and migraine. <i>Cephalalgia</i> , 2011, 31, 1320-1324.	1.8	25
70	The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D ₂ /A _{2A} Receptor Interaction in the Striatum: Implications for Parkinson's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 1850-1862.	1.7	140
71	Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. <i>Epilepsia</i> , 2010, 51, 274-279.	2.6	84
72	Impaired Plasticity at Specific Subset of Striatal Synapses in the Ts65Dn Mouse Model of Down Syndrome. <i>Biological Psychiatry</i> , 2010, 67, 666-671.	0.7	28

#	ARTICLE	IF	CITATIONS
73	Hippocampal Synaptic Plasticity, Memory, and Epilepsy: Effects of Long-Term Valproic Acid Treatment. <i>Biological Psychiatry</i> , 2010, 67, 567-574.	0.7	68
74	Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. <i>Experimental Neurology</i> , 2010, 221, 217-224.	2.0	28
75	Decreased NR2B Subunit Synaptic Levels Cause Impaired Long-Term Potentiation But Not Long-Term Depression. <i>Journal of Neuroscience</i> , 2009, 29, 669-677.	1.7	126
76	Obsessive-Compulsive Disorder and Migraine With Medication-Overuse Headache. <i>Headache</i> , 2009, 49, 1005-1013.	1.8	56
77	A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. <i>Experimental Neurology</i> , 2009, 217, 231-234.	2.0	19
78	Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy. <i>Epilepsy and Behavior</i> , 2009, 14, 269-270.	0.9	4
79	Hyperhomocysteinemia and retinal vascular changes in patients with epilepsy. <i>Epilepsy Research</i> , 2008, 81, 86-89.	0.8	5
80	Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study. <i>Epilepsy Research</i> , 2008, 82, 223-226.	0.8	62
81	A ¹ H magnetic resonance spectroscopy study in patients with obstructive sleep apnea. <i>European Journal of Neurology</i> , 2008, 15, 1058-1064.	1.7	34
82	Antiepileptic Drugs on Calcium Currents Recorded from Cortical and PAG Neurons: Therapeutic Implications for Migraine. <i>Cephalalgia</i> , 2008, 28, 1315-1326.	1.8	37
83	Polymyography in the diagnosis of childhood onset movement disorders. <i>European Journal of Paediatric Neurology</i> , 2008, 12, 480-483.	0.7	11
84	Degradation of endocannabinoids in chronic migraine and medication overuse headache. <i>Neurobiology of Disease</i> , 2008, 30, 186-189.	2.1	71
85	Plasticity and repair in the post-ischemic brain. <i>Neuropharmacology</i> , 2008, 55, 353-362.	2.0	132
86	Levetiracetam-associated hyponatremia. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2008, 17, 389-390.	0.9	21
87	Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition. <i>Journal of Neuroscience</i> , 2008, 28, 8040-8052.	1.7	54
88	Na ⁺ /Ca ²⁺ Exchanger Maintains Ionic Homeostasis in the Peri-Infarct Area. <i>Stroke</i> , 2007, 38, 1614-1620.	1.0	11
89	Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. <i>Neuropharmacology</i> , 2007, 53, 783-789.	2.0	53
90	Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. <i>Experimental Neurology</i> , 2007, 207, 218-226.	2.0	32

#	ARTICLE	IF	CITATIONS
91	Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. <i>European Journal of Neurology</i> , 2007, 14, 1176-1178.	1.7	81
92	Chronic Cocaine Prevents Depotentiation at Corticostriatal Synapses. <i>Biological Psychiatry</i> , 2006, 60, 436-443.	0.7	43
93	Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity. <i>Neuroscience</i> , 2006, 140, 897-911.	1.1	84
94	Tiagabine and vigabatrin reduce the severity of NMDA-induced excitotoxicity in chick retina. <i>Experimental Brain Research</i> , 2006, 171, 511-515.	0.7	6
95	Pathways of neurodegeneration and experimental models of basal ganglia disorders: Downstream effects of mitochondrial inhibition. <i>European Journal of Pharmacology</i> , 2006, 545, 65-72.	1.7	22
96	Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: Role of Na ⁺ /K ⁺ ATPase. <i>Neurobiology of Disease</i> , 2006, 23, 54-60.	2.1	51
97	Multiple Mechanisms Underlying the Neuroprotective Effects of Antiepileptic Drugs Against In Vitro Ischemia. <i>Stroke</i> , 2006, 37, 1319-1326.	1.0	95
98	Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1. <i>Neuron</i> , 2005, 45, 489-496.	3.8	485
99	Chronic Haloperidol Promotes Corticostriatal Long-Term Potentiation by Targeting Dopamine D2L Receptors. <i>Journal of Neuroscience</i> , 2004, 24, 8214-8222.	1.7	90
100	Coactivation of GABA A and GABA B Receptor Results in Neuroprotection During In Vitro Ischemia. <i>Stroke</i> , 2004, 35, 596-600.	1.0	89
101	Intracellular Calcium Increase in Epileptiform Activity: Modulation by Levetiracetam and Lamotrigine. <i>Epilepsia</i> , 2004, 45, 719-728.	2.6	124
102	Levetiracetam protects against kainic acid-induced toxicity. <i>Life Sciences</i> , 2004, 74, 1253-1264.	2.0	61
103	The Concept of 'Neuroprotection' in Neurological Diseases. <i>Current Neuropharmacology</i> , 2004, 2, 261-263.	1.4	0
104	Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. <i>Experimental Neurology</i> , 2003, 182, 461-469.	2.0	18
105	Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. <i>Neuropharmacology</i> , 2003, 44, 8-16.	2.0	86
106	Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? insights from in vitro studies. <i>Neurobiology of Disease</i> , 2003, 12, 82-88.	2.1	40
107	Identification of amoebae in the CSF in a patient with meningoencephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1445-a-1446.	0.9	6
108	Effects of Psychotropic Drugs on Seizure Threshold. <i>Drug Safety</i> , 2002, 25, 91-110.	1.4	301